The European Commission has approved Gilead Sciences' twice-yearly injection of lenacapavir (Yeytuo or Yeztugo) for HIV prevention[1][2][3]. The preparation has shown almost 100% effectiveness in preventing HIV infection in clinical studies[1]. The US FDA approved it in June, after which the European Medicines Agency (EMA) recommended approval for 27 EU states plus Iceland, Norway and Liechtenstein[1][2][3]. The development of the injection was led by Czech virologist Tomáš Cihlář, vice president of Gilead Sciences[1][2]. In the US, it costs more than $28,000 a year, which affects reimbursement by insurance companies[1][3]. HIV infects approximately 1.3 million people annually and causes about 630,000 deaths, with over 40 million people infected[1][2].